Skip to content
Home/Companies/Biotech/Calliditas
CA

Calliditas

Biotech·Sweden·Exited 2024·Held 4yr

Calliditas is a healthcare / biotech company, headquartered in Sweden.

Entry
2020
Hold
4yr
Exit
2024
Est. EV
–

Who owns Calliditas?

Calliditas was owned by Sofinnova Partners through Sofinnova Crossover Fund I (2018 vintage) from 2020 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC

Key facts

HQSweden
SectorHealthcare / Biotech
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

GenSight Biologics
Active
BiotechFrance
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUnited Kingdom· 2021
to
Artios Pharma
Active
BiotechUK· 2020
Hemab Therapeutics
Active
BiotechDenmark· 2020
F2G
Active
BiotechUK· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
2NA FISH
Active
Gruenderfonds RuhrGermany· 2026
Data refreshed weekly · Sourced from public filings